Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment

Authors :: Alan F. List
Ralf C. Bargou
Hermann Einsele
Denise Cosgrove
Stefan Knop
Source :: Leukemia & Lymphoma. 49:346-349
Publication Year :: 2008
Publisher :: Informa UK Limited, 2008.

Subjects :: Cancer Research
medicine.medical_specialty
business.industry
Treatment outcome
MEDLINE
Hematology
Clinical trial
Oncology
Internal medicine
medicine
In patient
business
Lenalidomide
medicine.drug

Tools